Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators: structure, function, and clinical use.

C K Osborne1, H Zhao, S A Fuqua

  • 1Breast Center and Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. kosborne@bmc.tmc.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 30, 2000
PubMed
Summary

Selective estrogen receptor modulators (SERMs) offer targeted approaches to block estrogen's effects, crucial for breast cancer treatment and prevention. Ongoing research aims to develop safer and more effective SERMs for various women's health conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Breast cancer research and treatment·2017
Same author

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.

Breast cancer research and treatment·2012
Same author

Systemic mirnas as potential biomarkers for malignancy.

International journal of cancer·2012
Same author

A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.

Molecular endocrinology (Baltimore, Md.)·2011
Same author

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Breast cancer research and treatment·2010

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Estrogen plays a vital role in physiological processes, but prolonged stimulation can drive breast cancer development.
  • Estrogen receptor (ER)-targeted therapies are crucial for managing ER-positive breast cancer.

Purpose of the Study:

  • To explore the mechanism and therapeutic potential of selective estrogen receptor modulators (SERMs).
  • To discuss the clinical applications and future development of SERMs in women's health.

Main Methods:

  • Review of scientific literature on estrogen, ER, and SERMs.
  • Analysis of SERM mechanism of action, including receptor binding and coregulatory protein interactions.
  • Evaluation of clinical efficacy and potential applications of tamoxifen and other SERMs.

Related Experiment Videos

Main Results:

  • Tamoxifen, a SERM, effectively treats ER-positive metastatic and adjuvant breast cancer.
  • SERMs modulate ER activity, exhibiting tissue-specific estrogenic or antiestrogenic effects.
  • SERMs hold promise for osteoporosis, other estrogen-regulated malignancies, and hormone replacement therapy.

Conclusions:

  • SERMs represent a significant advancement in targeting estrogen-mediated diseases.
  • Further development of SERMs aims to enhance efficacy and reduce toxicity for broader clinical use.
  • Future SERM agents may offer novel strategies for maintaining women's health.